|
**Overview**: Methylmalonic Acid Quantitative Panel**Introduction**: The Methylmalonic Acid Quantitative Panel is a diagnostic tool designed to assess vitamin B12 deficiency using urine samples. In India, vitamin B12 deficiency affects ~40-70 percent of vegetarians/vegans and elderly, causing macrocytic anemia and subacute combined degeneration; MMA elevation is more specific than B12 level alone for functional deficiency. High morbidity from under-testing in rural/low-SES populations with vegetarian diet or malabsorption, limited labs, delayed B12 supplementation leading to irreversible neuropathy or cognitive decline. Per biochemistry practices aligned with ICMR and Indian Journal of Hematology guidelines, the test employs spectrophotometry for methylmalonic acid and creatinine (for ratio) over 1-2 days with high accuracy, valuable for confirming B12 deficiency when serum B12 is borderline. This diagnostic falls under metabolic screening and targets patients with macrocytic anemia, neuropathy, or low-normal B12, addressing accurate detection to guide IM/oral B12 therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise functional deficiency assessment and reducing neurological complications. Its urine-based approach ensures reliable metabolite quantification.**Other Names**: MMA Quant Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Urinary MMA standard for B12 deficiency; in India, used in neurology/hematology.**Purpose**: The test assesses 2 parameters including methylmalonic acid to guide B12 deficiency assessment, confirm functional deficiency, inform supplementation.**Test Parameters**: 1. Methylmalonic Acid, 2. Creatinine.**Pretest Condition**: No fasting required; patients should have suspected B12 deficiency.**Specimen**: 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on diet, neuropathy, anemia.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated B12 deficiency including neuropathy, benefits of screening, and minimal discomfort from urine collection.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or renal impairment can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated MMA indicates functional B12 deficiency, necessitating specialist input.**Specialist Consultation**: Hematologists or neurologists should be consulted for management.**Additional Supporting Tests**: Serum B12, homocysteine for confirmation.**Test Limitations**: Renal function affects excretion; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Metabolic Studies India 2023. |
